journal article·2017-10-03Open access

Development and optimization of apigenin-loaded transfersomal system for skin cancer delivery: in vitro evaluation

Manmohan Singh Jangdey, Anshita Gupta, Shailendra Saraf, Swarnlata Saraf

Abstract

The aim of this work is to apply Box-Behnken design to optimize the transfersomes were formulated by modified rotary evaporation sonication technique using surfactant Tween 80. The response surface methodology was used having three-factored with three levels. The prepared formulations were characterized for vesicle shape, size, entrapment efficiency (%), stability, and in vitro permeation. The result showed that drug entrapment of 84.24% with average vesicle size of 35.41 nm and drug loading of 8.042%. Thus, optimized formulation was found good stability and is a promising approach to improve the permeability of apigenin in sustained release for prolonged period of time.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Bee Products Chemical Analysis · Essential Oils and Antimicrobial Activity

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C. G.), India

References (33)

Show source-provided references
1. Abdallah MH. · Int J Pharm Pharm Sci · 2013 · 5 · 560
2. Ali MS · World J Pharmacy Pharmaceut Sci · 2012 · 1 · 839
3. 10.3109/03639045.2015.101116710.3109/03639045.2015.1011167 ↗
4. 10.1016/0005-2736(92)90154-E10.1016/0005-2736(92)90154-E ↗
5. 10.1016/S0005-2736(97)00177-610.1016/S0005-2736(97)00177-6 ↗
6. Ding S · Int J Nanomed · 2014 · 9 · 327
7. 10.1155/2011/41831610.1155/2011/418316 ↗
8. 10.3109/03639045.2015.103827410.3109/03639045.2015.1038274 ↗
9. 10.1016/j.ijpharm.2006.05.02710.1016/j.ijpharm.2006.05.027 ↗
10. 10.1016/j.ijpharm.2008.01.02010.1016/j.ijpharm.2008.01.020 ↗
11. 10.3109/03639045.2015.109349610.3109/03639045.2015.1093496 ↗
12. 10.1016/j.ijpharm.2004.12.02210.1016/j.ijpharm.2004.12.022 ↗
13. Gupta A · Artif Cells Nanomed Biotechnol · 2016 · 44 · 960
14. 10.1081/DDC-12002545810.1081/DDC-120025458 ↗
15. 10.1021/mp800193n10.1021/mp800193n ↗
16. 10.3109/10717544.2014.90214610.3109/10717544.2014.902146 ↗
17. 10.3390/cancers202039710.3390/cancers2020397 ↗
18. 10.1039/C1NR11271F10.1039/C1NR11271F ↗
19. Mukerje A · Anticancer Res · 2009 · 29 · 3867
20. Nasr M · Drug Dev Ind Pharm · 2016 · 42 · 63610.3109/03639045.2015.1062512 ↗
21. 10.3109/03639045.2015.110434610.3109/03639045.2015.1104346 ↗
22. Patel D · Int J Oncol · 2007 · 30 · 233
23. Patel R · J Pharm Sci Res · 2009 · 1 · 71
24. 10.3109/03639045.2015.110708910.3109/03639045.2015.1107089 ↗
25. 10.3109/03639045.2015.107183210.3109/03639045.2015.1071832 ↗
26. Saraf S · Afr J Pharm Pharmacol · 2011 · 5 · 1054
27. 10.1517/17425247.2014.89158110.1517/17425247.2014.891581 ↗
28. 10.1016/j.ijpharm.2011.08.01810.1016/j.ijpharm.2011.08.018 ↗
29. 10.1016/j.ijpharm.2013.11.01710.1016/j.ijpharm.2013.11.017 ↗
30. 10.1128/MCB.01282-0610.1128/MCB.01282-06 ↗
31. Walve JR · Int J App Bio Pharm Tech · 2011 · 2 · 204
32. 10.1158/0008-5472.CAN-07-276310.1158/0008-5472.CAN-07-2763 ↗
33. 10.1016/j.powtec.2009.09.00410.1016/j.powtec.2009.09.004 ↗